Vitalgen's Cutting-Edge Gene Editing and Delivery Platforms to be Featured at AACR Annual Meeting 2025
Collaborative research with Grit Biotechnology showcases Vitalgen's proprietary platform and delivery systems in oncology applications
'These AACR presentations showcase how our proprietary platforms can enable breakthrough therapies across multiple therapeutic areas through strategic collaborations'— Dr. Xiaoping Zhao, Ph.D., CEO
CHICAGO, IL, UNITED STATES, April 15, 2025 / EINPresswire.com / -- Vitalgen BioPharma Co., Ltd. ('Vitalgen'), a pioneer in transformative gene therapy technologies, today announced its collaborative research with Grit Biotechnology Co., Ltd. ('Grit Bio') will be featured in two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago from April 25th to 30th.
The presentations highlight the versatility and efficacy of Vitalgen's proprietary technology platforms in oncology applications, demonstrating the company's ability to form productive partnerships across therapeutic areas.
'These AACR presentations showcase how our proprietary platforms can enable breakthrough therapies across multiple therapeutic areas through strategic collaborations,' said Dr. Xiaoping Zhao, Ph.D., CEO and Co-founder of Vitalgen. 'While we maintain our internal focus, our technology platforms—particularly our ViCas® CRISPR gene-editing platform and ViLNP® delivery systems—have proven valuable in advancing development of novel cancer therapies through partnerships.'
The collaborative research being presented includes advancements in gene-edited tumor-infiltrating lymphocyte (TIL) therapy and next-generation neoantigen cancer vaccines. Specifically, Grit Bio will present data on their development a next-generation dual-knockout TIL product, GT300, which utilizes Vitalgen's proprietary AaCas12bMax gene-editing technology, showing superior editing safety profile and enhanced expansion and cell fitness compared to their SpCas9-edited counterparts. Moreover, a novel neoantigen cancer vaccine GT600 approach combining Grit Bio's NEOvigator™ neoantigen identification platform with Vitalgen's APC-targeted LNP delivery system Dakini™ will be presented. Both GT300 and GT600 are under clinical assessment.
'The AaCas12bMax system represents a significant leap forward in gene-editing technology, offering potent on-target editing efficiency with a proven superior safety profile compared to the conventional editors,' said Dr. Xi Zhu, Ph.D., Head of Translational Research at Vitalgen. 'Precise editing fidelity combined with good cellular fitness and expansion capacity post editing are critical determinants for the development of engineered cell therapies. Our collaboration with Grit Bio validates the translational potential of AaCas12bMax in advancing the development of next-generation gene-editing products with enhanced safety profile and therapeutic potential.'
Vitalgen's technology platforms featured in the presentations include:
1. ViCas® CRISPR DNA Editing Platform:
-Featuring the AaCas12bMax system, which offers efficiency gene editing with negligible off-target gene editing
-Enhanced cellular fitness and expansion capacity post AaCas12bMax editing during manufacture
2. ViLNP® Dakini:
An Antigen Presenting Cell (APC)-specific delivery LNP with efficiency of antigen-specific T cell induction exceeding comparable technologies by more than 10-fold without detectable hepatocyte delivery following systemic administration.
Since its founding in March 2020, Vitalgen has raised $160 million through Series B+ funding and developed a robust pipeline with two programs in Phase III, two in Phase I/II, and four in IIT studies. The company has built comprehensive infrastructure including 2,500 m² of R&D facilities and 8,500 m² of GMP-compliant manufacturing space in Shanghai.
About Vitalgen
Vitalgen BioPharma Co., Ltd. is a patient-focused, innovation-driven biotechnology company developing transformative gene therapies. With vertically integrated proprietary platforms, Vitalgen focuses on rare and common diseases while enabling partners to leverage its technologies across multiple therapeutic areas. Founded in 2020 and headquartered in Shanghai, China, Vitalgen operates state-of-the-art facilities compliant with both China GMP and US cGMP standards. For more information, visit www.vitalgen.com.
About Grit Bio
GRIT Bio was founded in 2019 as an innovative biopharmaceutical company, focused on immune cell treatments for oncology and characterized by a R&D pipeline in TIL therapies. GRIT Bio has completed multiple rounds of equity financing and is backed by renowned venture capital funds. GT101, a proprietary injectable developed by GRIT Bio, is the first TIL therapy that entered registrational clinical trial. GT 101 is currently in pivotal Phase II clinical study. GRIT Bio's GT201 injectable, the first TIL therapy with membrane-bound IL-15 complex, has cleared IND in both US and China. Core R&D platforms of the company include StemTexp® stemness TIL expansion platform, StaViral® stably virus transfected cell lines, ImmuT Finder® immune modulator target discovery platform, and KOReTIL® high-efficiency gene knock-out system. Based on the platforms, GRIT Bio generated a series of next-generation gene-edited TIL therapies. With internationally advanced technology reserve and industry resources, GRIT Bio aims to develop breakthrough therapies for solid tumors and bring new hope to cancer patients. For further information, please visit: www.grit-bio.com
Forward-Looking Statements
This press release contains forward-looking statements about Vitalgen BioPharma Co., Ltd. based on management's current expectations, which are subject to known and unknown uncertainties and risks. Words such as 'anticipated,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' 'may,' 'will,' and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding our expectations for our technology platforms, gene therapy candidates in development, collaborations, and plans for commercialization. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, the risk inherent in developing pharmaceutical product candidates, conducting successful clinical trials, and obtaining regulatory approvals. Except as required by law, Vitalgen assumes no obligation to update any forward-looking statements contained herein as a result of new information, future events, or otherwise.
David Wu
Vitalgen BioPharma
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
CEOs of The LYCRA Company and Qore ® Join Global Fashion Summit Lineup
WILMINGTON, Del.--(BUSINESS WIRE)-- The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore ®, the maker of QIRA ®, a next-generation BDO and a key ingredient in bio-derived LYCRA ® fiber, which is launching later this year. The CEOs of The LYCRA Company and Qore® will discuss the development of bio-derived LYCRA® fiber made with QIRA®, made from annually renewable field corn, during their Fireside Chat at the Global Fashion Summit: From Farm to Fashion. Share Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social. This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA ® fiber made with QIRA ®. Here, visitors can be transported to the Qore ® site and cornfields in Iowa through a virtual reality experience. Bio-derived LYCRA ® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA ® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA ® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe. 'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore ® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.' The newly constructed Qore ® site in Eddyville, Iowa, began operating last month and has started producing QIRA ®. The company will host a grand opening celebration in July. 'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore ®, but for the entire industry,' said Jon Veldhouse, CEO of Qore ®. 'With QIRA ® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Learn more about this renewable offering by visiting *Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA ® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc. About The LYCRA Company The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA ®, LYCRA HyFit ®, LYCRA ® T400 ®, COOLMAX ®, THERMOLITE ®, ELASPAN ®, SUPPLEX ® and TACTEL ® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at About Qore ® LLC Formed through a joint venture by Cargill and HELM AG, Qore ® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA ®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA ® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA ® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit About The Global Fashion Summit Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at
Yahoo
an hour ago
- Yahoo
CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup
LYCRA® Brand and QIRA® are Principal Sponsors of the 2025 Copenhagen Edition WILMINGTON, Del., June 02, 2025--(BUSINESS WIRE)--The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year. Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social. This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience. Bio-derived LYCRA® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe. "We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion," said Gary Smith, CEO of The LYCRA Company. "Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals." The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July. "Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry," said Jon Veldhouse, CEO of Qore®. "With QIRA® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market." Learn more about this renewable offering by visiting *Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc. About The LYCRA Company The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at About Qore® LLC Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit About The Global Fashion Summit Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at LYCRA® is a trademark of The LYCRA Company. QIRA® is a trademark of Qore®. View source version on Contacts Karie J. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
